Catalog No.
DHC90702
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
4.13 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
2H7, PR-070769 / PR070769 / R-1594 / RG-1594, CAS: 637334-45-3
Clone ID
Ocrelizumab
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, PMID: 28002679
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, PMID: 28002688
Ocrelizumab: A Review in Multiple Sclerosis, PMID: 30171504
Ocrelizumab and Other CD20 + B-Cell-Depleting Therapies in Multiple Sclerosis, PMID: 28695471
Ocrelizumab: its efficacy and safety in multiple sclerosis, PMID: 29897610
[Ocrelizumab for treatment of multiple sclerosis], PMID: 32524163
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study, PMID: 32727835
Ocrelizumab, PMID: 31613530
Ocrelizumab: a new milestone in multiple sclerosis therapy, PMID: 29774057
Ocrelizumab for the treatment of multiple sclerosis, PMID: 30570368
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab, PMID: 33092190
COVID-19 in ocrelizumab-treated people with multiple sclerosis, PMID: 33482590
Ocrelizumab, PMID: 31643475
Ocrelizumab for multiple sclerosis, PMID: 30116083
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis, PMID: 31484710
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis, PMID: 30677733
Ocrelizumab, PMID: 29999962
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database, PMID: 32820687
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies, PMID: 30844611
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis, PMID: 30820738
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases, PMID: 32671831
Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 32048205
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis, PMID: 32645640
Ocrelizumab-Induced Severe Colitis, PMID: 33354373
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, PMID: 22047971
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension, PMID: 32690791
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial, PMID: 33129442
Dermatographism associated with ocrelizumab, PMID: 32979732
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?, PMID: 32315980
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series, PMID: 32570202
Ocrelizumab initiation in patients with MS: A multicenter observational study, PMID: 32273482
Long-term ocrelizumab in progressive multiple sclerosis, PMID: 33129443
Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany, PMID: 32920498
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination, PMID: 32780300
Ocrelizumab for multiple sclerosis, PMID: 30008443
Formulary Drug Review: Ocrelizumab, PMID: 29276296
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis, PMID: 29232960
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis, PMID: 27552111
Ocrelizumab for primary progressive multiple sclerosis, PMID: 31279744
Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis, PMID: 32607256
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness, PMID: 33370649
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review, PMID: 32799563
Endocarditis following ocrelizumab in relapsing-remitting MS, PMID: 32014890
Ocrelizumab: a B-cell depleting therapy for multiple sclerosis, PMID: 28658986
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO, PMID: 33202059
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population, PMID: 33369288
Switching from natalizumab to ocrelizumab in patients with multiple sclerosis, PMID: 32552363
Pharmacoeconomic Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited) [Internet], PMID: 30462439
Clinical Review Report: Ocrelizumab (Ocrevus): (Hoffmann-La Roche Limited) [Internet], PMID: 30457779
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?, PMID: 32619884
For research use only. Not for human or drug use.
